A Phase 1 Dose Escalation, Safety and Tolerability Study of Jaktinib in Patients With Primary Myelofibrosis (PMF) or Post-polycythemia Vera/Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) and Who Are Relapsed/ Refractory to a Marketed JAK Inhibitor
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Diagnosis of myelofibrosis (primary, post-polycythemia vera, or post-essential thrombocythemia).
• Relapsed/refractory to a marketed (FDA approved) JAK inhibitor.
• At least 18 years of age.
• ECOG PS 0, 1, or 2.
• Expected life expectancy is greater than 24 weeks.
Locations
United States
Ohio
Site 01
RECRUITING
Canton
Contact Information
Primary
Jason Wu, M.D
wujs@zelgen.com
+86-21-58942758
Time Frame
Start Date: 2024-07-01
Estimated Completion Date: 2025-11-30
Participants
Target number of participants: 26
Treatments
Experimental: Jaktinib
Related Therapeutic Areas
Sponsors
Leads: Suzhou Zelgen Biopharmaceuticals Co.,Ltd